



An ambitious EU Trade Strategy focused on jobs, growth and health



As Pfizer, we serve patients in over 170 countries and have a strong presence across the world, including in the European Union (EU). As such, we depend on an open, predictable, rules-based global trading environment to ensure that patients around the world can access our medicines.

EU Trade Policy supports innovation and access to medicines

OUR MEDICINES
AND VACCINES
REACH PATIENTS

IN MORE THAN
170
COUNTRIES

◆ **Global trade is a major driver for jobs and growth in Europe.** Nowhere is this more evident than in the innovative pharmaceutical sector. Despite an often challenging environment in Europe, and increasingly protectionist policies outside of Europe, exports of medicines have been a source of economic resilience.¹ Pfizer alone employs thousands of people who research, develop and manufacture medicines in sites across Europe, and export them around the world.²

WE EMPLOY
> 18.000
PEOPLE IN EUROPE

of which
> 8.000
IN MANUFACTURING

◆ This work is underpinned by the EU's external trade policies, in areas such as removal of protectionist barriers, safeguarding of effective regulations, and fostering effective intellectual property (IP) protections. Taken together, these help to **create an environment for continued investment in healthcare innovation, and to ensure access to medicines for patients.**

- ◆ Free trade agreements (FTAs) provide a win-win by removing trade barriers, helping to make medicines available to a greater number of patients, and increasing global competitiveness.
- ◆ At Pfizer we believe that **IP rights** are critical to foster innovation and provide incentives for future R&D investment. We support efforts to strengthen IP rights and enforcement in FTAs negotiated by the European Union, the United States and other countries.
- ◆ Our sector's ability to operate in the EU is underpinned by a world-leading, science-based regulatory framework. Internationally, the EU plays a critical role in advancing both its own, and globally-recognised, standards (e.g. WHO), raising the bar globally.

60% OF OUR PRODUCTS
GLOBALLY
are handled in the
PFIZER LOGISTICS CENTRE
IN ZAVENTEM, BELGIUM

Key policy challenges and opportunities:

- ◆ Amid a global pandemic, and at a time of increasing protectionism, **effective trade policy has never been more important to ensuring vaccines, medicines and other critical goods reach patients around the world.**
- ◆ Open, rules-based trade is also vital to global economic recovery, with institutions such as the **World Trade Organisation (WTO)** playing a crucial role for rules that support trade-enabled jobs and economic development.
- ◆ **Relations with the United States** are built on deep economic ties and shared values. The EU and US should champion transatlantic cooperation, including to support world-leading life science innovation.
- ◆ To remain a leader in life sciences innovation and manufacturing, Europe must promote policies that drive competitiveness and enable trade with **growing markets.**
- ◆ Trade policies should reflect the evolution of technology. **Forward-looking regulatory and digital trade provisions** can support life sciences R&D, and patient access to innovative, safe and effective medicines around the world.
- ◆ As countries negotiate new trade rules, it is equally important that they continue to **implement and enforce existing rules.** This is necessary to ensure the benefits of free trade for all members of the global trading system.

Key Policy Points:

Under the Commission's new Trade Strategy, we call on the EU to:

- 1 Drive resilience by defending open trade and global supply chains, underpinned by a rules-based trading system and effective enforcement.
- 2 Build on the depth of existing ties with the United States.
- 3 Secure as close as possible a future relationship with the United Kingdom.
- 4 Seize major trading opportunities, notably in the Asia-Pacific region.
- 5 Not only maintain Europe's own high IP standards, but continue to advocate for effective IP globally, enabling innovation to flourish.